WO2000025140A1 - Method for determining platelet count - Google Patents
Method for determining platelet count Download PDFInfo
- Publication number
- WO2000025140A1 WO2000025140A1 PCT/US1999/024670 US9924670W WO0025140A1 WO 2000025140 A1 WO2000025140 A1 WO 2000025140A1 US 9924670 W US9924670 W US 9924670W WO 0025140 A1 WO0025140 A1 WO 0025140A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ofthe
- antibody
- particles
- platelet
- agglutination
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Definitions
- Field ofthe Invention This invention relates to the field of diagnostic assays and in particular to the determination ofthe number of platelets in a sample.
- platelets in mammalian physiology are extraordinarily diverse, but their primary role is in promoting hemostasis. In many situations, an evaluation ofthe ability of blood to clot is desired, a parameter that is frequently controlled by the ability of platelets to adhere and/or aggregate. Thus, one may wish to assess the adhesive functions of platelets. For example, one may wish to know whether to administer drugs that will block, or promote, clot formation, or one may need to detect deficiencies in platelet function prior to surgical procedures. In other instances one may be interested in evaluating the effectiveness of a platelet inhibitor that is being tested as a new drug or is being used as approved clinical treatment in a patient.
- Platelets are known to aggregate under a variety of conditions and in the presence of a number of different reagents. Platelet aggregation is a term used to describe the binding of platelets to one another. The phenomenon can be induced by adding aggregation-inducing agents to platelet-rich plasma (PRP) or to whole blood. Platelet aggregation in vitro depends upon the ability of platelets to bind fibrinogen to their surfaces after activation by an aggregation-inducing agent such as ADP or collagen. Platelets play a critical role in the maintenance of normal hemostasis. When exposed to a damaged blood vessel, platelets will adhere to exposed sub-endothelial matrix.
- PRP platelet-rich plasma
- ADP aggregation-inducing agent
- a rapid platelet function assay has recently been developed and is described in U.S. Patent No. 5,763,199 (Coller).
- the assay determines glycoprotein Ilb/IIIa receptor blockade in whole blood. Agglutination of small polymeric beads coated with a glycoprotein Ilb/IIIa ligand such as fibrinogen results when the beads are contacted with whole blood containing platelets with glycoprotein Ilb/IIIa receptors that are not blocked. Failure to agglutinate indicates that blockade ofthe GPIIb/IIIa receptors has been achieved.
- the addition of a thrombin receptor activator results in an assay that is rapid and convenient enough to be performed at bedside and that results in agglutination ofthe small polymeric beads within a convenient, known period of time if the glycoprotein Ilb/IIIa receptors are not blocked.
- the assay includes the ability to transfer blood to be tested from a collection container to an assay device without opening the collection container. This platelet aggregation assay can be conducted at the same time as the activated clotting time (ACT), which is performed to assess the adequacy of heparinization.
- ACT activated clotting time
- periodic monitoring may also be desirable.
- the effect ofthe GPIIb/IIIa antagonist may be desirable to rapidly determine whether the effect ofthe GPIIb/IIIa antagonist has worn off sufficiently to allow the surgery or procedure to be performed without further interventions to reverse the effect ofthe GPIIb/IIIa inhibitor.
- a rapid measure of platelet function may be helpful in determining whether the bleeding is due to a high or toxic level of platelet inhibition.
- the level of platelet inhibition may also be helpful in guiding whether to reverse the drug effect with platelet transfusions or look for other causes of bleeding.
- the number of platelets in a plasma sample may be determined by electornic particle enumeration using, for example, an instrument manufactured by Coulter Electronics (Hialeah, Florida).
- a whole blood analyzer such as, for example, an instrument manufactured by Sysmex Corporation of America (Long Grove, IL), is used. This instrument measures all cells in the whole blood.
- GPIb ⁇ is a component ofthe GPIb/IX-V complex that is involved in platelet adhesion to exposed subendothelium via interaction with von Willebrand factor (vWf).
- the GPIb/IX-N complex also serves as a high affinity thrombin (Flla) receptor and is usually absent on platelets from patients having Bernard-Soulier syndrome.
- GPIb/IX is a member of the leucine-rich family of glycoprotein receptors and is highly negatively charged.
- GPIb is composed of GPIb ⁇ bonded by a disulfide linkage to GPIb ⁇ . GPIb exists in a non-covalent 1 : 1 complex with GPIX.
- GPIb/IX forms a 2:lstoichiometric non-covalent complex with GPV.
- Evidence also suggests that GPIb/IX-V is in close proximity to and may associate with the platelet IgG receptor Fc ⁇ RII.
- GPIb ⁇ is a rod-like structure extending about 60 nm from the platelet surface and it is this long extension that likely facilitates interaction with the subendothelium.
- the GPIIb/IIIa receptor extends only about 10 to 20 nm from the platelet surface.
- the extracellular portion of GPIb ⁇ is cleaved from the platelet surface by a variety of proteases releasing a soluble fragment, glycocalicin, which retains the vWf and Flla binding sites.
- a schematic ofthe GPIb-IX-V complex is depicted in Fig. 1.
- Ruan, et al. disclose a monoclonal antibody to human platelet glycoprotein I in Br. J. Haematol. (1981) 49:501-509 and 511-519.
- Michelson discusses flow cytometry: a clinical test of platelet function in Blood (1996) 87:4925-4936.
- Fox, et al. disclose a structure for the glycoprotein Ib-IX complex from platelet membranes in J. Biol. Chem. (1988) 263:4882-4890.
- U.S. Patent No. 4,948,961 discloses hybridomas and monoclonal antibodies that specifically bind to GPIb on platelets and inhibit the binding of thrombin to platelets.
- Ward, et al. discuss mocarhagin, a novel cobra venom metalloproteinase that cleaves the platelet von Willebrand factor receptor glycoprotein Ib ⁇ and the identification ofthe sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ib ⁇ as a binding site for von Willebrand factor, ⁇ -thrombin, and several anti GPIb ⁇ monoclonal antibodies in Biochemistry (1996) 35:4929-4938.
- One aspect ofthe invention concerns a method for determining the number of platelets in a sample.
- a liquid medium comprising the sample and a matrix with which is associated a molecule that binds to a platelet cell surface glycoprotein receptor is subjected to agglutination conditions.
- the agglutination ofthe matrix is measured as an indication ofthe number of platelet-associated receptors present in the medium. The measurement above is then related to the number of platelets in the sample.
- Another aspect ofthe present invention is a method for determining the number of platelets in a whole blood sample.
- a liquid medium is prepared comprising the sample and particles to which is bound an antibody to a GPIb ⁇ subunit ofthe GPIb/lx-v receptor.
- the liquid medium is subjected to agglutination conditions.
- the agglutination ofthe particles is measured as an indication ofthe number of platelet-associated receptors present in the medium and the measurement is related to the number of platelets in the sample.
- Another aspect of the present invention is a kit for determining the number of platelets in a sample.
- the kit comprises in packaged combination (a) particles to which is bound an antibody to a GPIb ⁇ subunit ofthe GPIb/lx-v receptor and (b) a buffered medium.
- Fig. 1 is a schematic ofthe GPIb/IX-V complex.
- Fig. 2 A and 2B show the rate of agglutination of platelet rich plasma with covalent 6Dl-microparticles.
- Fig. 3 A and 3B show the rate of agglutination of platelet rich plasma with anti- GPIb ⁇ mAbs coated indirectly on anti-mouse IgG microparticles.
- Fig. 4 shows the kinetics of agglutination of platelets in whole blood with 6D1 microparticles.
- Fig. 5 illustrates that immobilized 6D1 -particles enumerate the platelets count in whole blood
- Fig. 6 shows the agglutination of PRP by immobilized non-GPIb antibodies.
- DETAILED DESCRIPTION OF THE INVENTION The present invention provides a method for enumeration of platelets in a whole blood sample. The method may be employed in conjunction with an assay for platelet function such as the rapid platelet function assay of U.S. Patent No. 5,763,199. Before proceeding further with a detailed description ofthe present invention, a number of terms as used herein are defined.
- Sample any solution, synthetic or natural, containing platelets, including body fluids such as, for example, whole blood, platelet-containing blood fractions such as platelet-rich plasma, and the like.
- the amount ofthe sample depends on the nature ofthe sample. For fluid samples such as whole blood, the amount ofthe sample is usually about 30 ⁇ l to 300 ⁇ l, more usually, about 160 ⁇ l.
- sample includes unprocessed samples directly from a patient or samples that have been pretreated and prepared in any convenient liquid medium although an aqueous medium is preferred. Preprocessing may include, for example, treatment with an anticoagulant.
- the sample is untreated whole blood or whole blood treated with an anticoagulant.
- Blood can be drawn from an individual being assessed for enumeration of platelets by any number of known techniques.
- the blood is drawn into a closed vessel such as a Vacutainer® tube to protect the individual who is drawing the blood from blood-borne infectious agents such as hepatitis B virus or the HIV virus.
- the blood may be drawn into a vessel containing anticoagulant or by adding anticoagulant to drawn blood.
- a sufficient amount ofthe anticoagulant is used to prevent coagulation ofthe whole blood as is well-known in the art.
- Suitable anticoagulants include EDTA, citrate, oxalate, heparin, hirudin or other antithrombin agents.
- Platelet cell surface glycoprotein receptor - a carbohydrate-rich protein receptor on the surface of a platelet cell.
- the receptor usually contains at least about 5 to about 10 % by weight of carbohydrate, and may contain up to about 70 % or more of carbohydrate.
- Such receptors may be, for example, GPIb ⁇ , (about 60 % carbohydrate), GPIIb/IIIa (about 15% carbohydrate) and the like.
- Binding molecule for a platelet cell surface glycoprotein receptor - a molecule that causes the aggregation ofthe receptor.
- the binding molecule may be a specific binding molecule or a non-specific binding molecule.
- Specific binding the specific recognition of one of two different molecules for the other compared to substantially less recognition of other molecules.
- Specific binding molecule ⁇ one of two different molecules having an area on the surface or in a cavity that specifically binds to, and is thereby defined as, complementary with a particular spatial and polar organization ofthe other molecule.
- the specific binding molecule may be a ligand for the platelet cell surface glycoprotein receptor such as von Willebrand factor, thrombin, alboaggregins (reviewed in Kowalski, et al., supra, and so forth.
- the specific binding molecule may be an antibody for the platelet cell surface glycoprotein receptor.
- Non-specific binding molecule - a molecule that is not a specific binding molecule but nonetheless binds to, or causes the aggregation of, the platelet cell surface glycoprotein receptor.
- non-specific binding molecules include, by way of illustration and not limitation, wheat germ agglutinin, concanavalin A, poly-L-lysine, and the like.
- a particular requirement for the binding molecule is that it be substantially free from binding to molecules, which might be present in a sample, other than the platelet cell surface glycoprotein receptor.
- Ligand - a molecule that is specifically recognized by and binds to another molecule.
- Associated with - a molecule may be associated with a matrix such as a particle by being non-specifically bound or specifically bound to the matrix, by being physically adsorbed on the surface ofthe matrix or by being dissolved in the matrix.
- Non-specific binding of a molecule to a matrix may be achieved by covalently bonding or attaching the molecule to the matrix.
- Matrix ⁇ a support comprised of an organic or inorganic, solid or fluid, water insoluble material, which may be transparent or partially transparent.
- the matrix can have any of a number of shapes, such as particle, including bead, film, membrane, tube, well, strip, rod, and the like.
- the surface ofthe matrix is, preferably, hydrophilic or capable of being rendered hydrophilic.
- the body ofthe matrix is, preferably, hydrophobic.
- the matrix may be suspendable in the medium in which it is employed. Examples of suspendable matrices in accordance with the present invention, by way of illustration and not limitation, are polymeric materials such as latex, lipid bilayers, oil droplets, cells and hydrogels.
- matrix compositions include polymers, such as nitrocellulose, cellulose acetate, poly (vinyl chloride), polyacrylamide, polyacrylate, polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polymethacrylate, poly(ethylene terephthalate), nylon, poly(vinyl butyrate), polysaccharides such as dextrans and modified dextrans, etc.; either used by themselves or in conjunction with other materials.
- polymers such as nitrocellulose, cellulose acetate, poly (vinyl chloride), polyacrylamide, polyacrylate, polyethylene, polypropylene, poly(4-methylbutene), polystyrene, polymethacrylate, poly(ethylene terephthalate), nylon, poly(vinyl butyrate), polysaccharides such as dextrans and modified dextrans, etc.; either used by themselves or in conjunction with other materials.
- Binding of molecules to the matrix may be direct or indirect, covalent or non- covalent and can be accomplished by well-known techniques, commonly available in the literature. See, for example, “Immobilized Enzymes,” Ichiro Chibata, Halsted Press, New York (1978) and Cuatrecasas, __ BioL Chem.. 245:3059 (1970).
- the surface ofthe matrix may be polyfunctional or be capable of being polyfunctionalized or be capable of binding to a molecule, or the like, through covalent or specific or non-specific non-covalent interactions. Such binding is indirect where non-covalent interactions are used and is direct where covalent interactions are employed.
- a wide variety of functional groups are available or can be incorporated. Functional groups include carboxylic acids, aldehydes, amino groups, cyano groups, ethylene groups, hydroxyl groups, mercapto groups and the like.
- the manner of linking a wide variety of compounds to surfaces is well known and is amply illustrated in the literature (see above). The length of a linking group to the molecule may vary widely, depending upon the nature ofthe molecule, the effect ofthe distance between the molecule and the surface on the specific binding properties and the like.
- the amount ofthe binding molecule employed is dependent on the size, affinity and structural characteristics ofthe molecule, and so forth and is usually best determined empirically.
- the molecule is present in from about 1 to about 100, more usually about 20 to about 100, frequently from about 30 to about 100, and in some cases preferably close to about 90 to about 100 mole percent ofthe molecules present on the surface ofthe matrix.
- Particles particles of at least about 0J microns and not more than about 10 microns, usually at least about 1 micron and less than about 6 microns.
- the particles can be virtually any shape, but are generally spherical with uniform diameters.
- the particle may have any density, but preferably of a density approximating water, generally from about 0.7 to about 1.5g/ml.
- the particles may or may not have a charge on the surface, either positive or negative, preferably negative.
- the particles may be solid (e.g., comprised of organic and inorganic polymers or latex), oil droplets (e.g., hydrocarbon, fluorocarbon, silicon fluid), or vesicles (e.g., synthetic such as phospholipid or natural such as cells and organelles).
- the solid particles are normally polymers, either addition or condensation polymers, which are readily dispersible in the liquid medium.
- the solid particles will also be adsorptive or functionalizable so as to bind or attach at their surface, either directly or indirectly, a molecule for binding to the platelet cell surface glycoprotein receptor.
- the solid particles can be comprised of polystyrene, polyacrylamide, homopolymers and copolymers of derivatives of acrylate and methacrylate, particularly esters and amides, silicones and the like.
- Oil droplets are water-immiscible fluid particles comprised of a lipophilic compound coated and stabilized with an emulsifier that is an amphiphilic molecule such as, for example, phospholipids, sphingomyelin, albumin and the like that exist as a suspension in an aqueous solution, i.e. an emulsion.
- the phospholipids are based upon aliphatic carboxylic acid esters of aliphatic polyols, where at least one hydroxylic group is substituted with a carboxylic acid ester of from about 8 to 36, more usually of from about 10 to 20 carbon atoms, which may have from 0 to 3, more usually from 0 to 1 site of ethylenic unsaturation and at least 1, normally only 1 , hydroxyl group substituted with phosphate to form a phosphate ester.
- the phosphate group may be further substituted with small aliphatic compounds that are difunctional or of higher functionality, generally having hydroxyl or amino groups.
- Emulsions comprising oil droplets can be made in accordance with conventional procedures by combining the appropriate lipophilic compounds with a surfactant, anionic, cationic, zwiterionic or nonionic, where the surfactant is present in from about 0J to 5, more usually from about 0J to 2 weight percent ofthe mixture and subjecting the mixture in an aqueous medium to agitation, such as sonication or vortexing.
- a surfactant anionic, cationic, zwiterionic or nonionic
- the surfactant is present in from about 0J to 5, more usually from about 0J to 2 weight percent ofthe mixture and subjecting the mixture in an aqueous medium to agitation, such as sonication or vortexing.
- Illustrative lipophilic compounds include hydrocarbon oils, halocarbons including fluorocarbons, alkyl phthalates, trialkyl phosphates, triglycerides, etc.
- the oil droplets can comprise a fluorocarbon oil or a silicone oil (silicon particle). Such droplets are described by Giaever in U.S. Patents Nos. 4,634,681 and 4,619,904 (the disclosures of which are incorporated herein in their entirety).
- Molecules can be bound to the droplets in a number of ways such as, for example, as described by Giaever, supra.
- the outer shell of a liposome consists of an amphiphilic bilayer that encloses a volume of water or an aqueous solution. Liposomes with more than one bilayer are referred to as multilamellar vesicles. Liposomes with only one bilayer are called unilamellar vesicles.
- the amphiphilic bilayer is frequently comprised of phospholipids.
- Phospholipids employed in preparing particles utilizable in the present invention can be any phospholipid or phospholipid mixture found in natural membranes including lecithin, or synthetic glyceryl phosphate diesters of saturated or unsaturated 12-carbon or 24-carbon linear fatty acids wherein the phosphate can be present as a monoester, or as an ester of a polar alcohol such as ethanolamine, choline, inositol, serine, glycerol and the like.
- Particularly preferred phospholipids include L-a-palmitoyl oleoyl-phosphatidylcholine (POPC), palmitoyl oleoylphosphatidyl-glycerol (POPG), L- ⁇ -dioleoylphosphatidylglycerol, L- ⁇ (dioleoyl)-phosphatidyl ethanolamine (DOPE) and L- ⁇ -(dioleoyl)-phosphatidyl-(4-(N-maleimidomethyl)-cyclohexane- 1 -carboxyamido) ethanol (DOPE-MCC).
- POPC L-a-palmitoyl oleoyl-phosphatidylcholine
- POPG palmitoyl oleoylphosphatidyl-glycerol
- DOPE L- ⁇ -dioleoylphosphatidyl ethanolamine
- DOPE-MCC L- ⁇ -(d
- Liposomes may be produced by a variety of methods including hydration and mechanical dispersion of dried phospholipid or phospholipid substitute in an aqueous solution. Liposomes prepared in this manner have a variety of dimensions, compositions and behaviors. One method of reducing the heterogeneity and inconsistency of behavior of mechanically dispersed liposomes is by sonication. Such a method decreases the average liposome size. Alternatively, extrusion is usable as a final step during the production ofthe liposomes.
- U.S. Patent 4,529,561 discloses a method of extruding liposomes under pressure through a uniform pore-size membrane to improve size uniformity.
- Liposomes and oil droplets will often have, for example, thiol or maleimide or biotin groups on the molecules comprising the lipid bilayer. Molecules may then be bound to the surface by reaction ofthe particles with one of these materials that is bound to a sulfhydryl reactive reagent, a sulfhydryl group, or avidin, respectively.
- Sulfhydryl reactive groups include, among others, activated disulf ⁇ des such as 2-pyridyl disulfides and alkylating reagents such as bromoacetamide and maleimide.
- Latex particles signifies a particulate water suspendable water insoluble polymeric material usually having particle dimensions of about OJ ⁇ to about 30 ⁇ , more usually about l ⁇ to about lO ⁇ , preferably, about 1 to about 6 ⁇ , in diameter.
- the latex is frequently a substituted polyethylene such as polystyrene-butadiene, polyacrylamide, polystyrene, polystyrene with carboxylic groups, polystyrene with amino groups, poly-acrylic acid, polymethacrylic acid, acrylonitrile-butadiene, styrene copolymers, polyvinyl acetate-acrylate, polyvinyl pyridine, vinyl-chloride acrylate copolymers, and the like.
- Non-crosslinked polymers of styrene and carboxylated styrene or styrene functionalized with other active groups such as amino, hydroxyl, halo and the like are preferred.
- copolymers of substituted styrenes with dienes such as butadiene will be used.
- Antibody an immunoglobulin that specifically binds to and is thereby defined as complementary with a particular spatial and polar organization of another molecule such as a platelet cell surface glycoprotein.
- the antibody can be monoclonal or polyclonal and can be prepared by techniques that are well known in the art such as immunization of a host and collection of sera (polyclonal) or by preparing continuous hybrid cell lines and collecting the secreted protein (monoclonal), or by cloning and expressing nucleotide sequences or mutagenized versions thereof coding at least for the amino acid sequences required for specific binding of natural antibodies.
- Antibodies may include a complete immunoglobulin or fragment thereof, which immunoglobulins include the various classes and isotypes, such as IgA, IgD, IgE, IgGl, IgG2a, IgG2b and IgG3, IgM, etc. Fragments thereof may include Fab, Fv and F(ab') 2 , Fab', and the like. In addition, aggregates, polymers, and conjugates of immunoglobulins or their fragments can be used where appropriate so long as binding affinity for a particular molecule is maintained.
- Antiserum containing antibodies is obtained by well-established techniques involving immunization of an animal, such as a rabbit, guinea pig, or goat, with an appropriate immunogen and obtaining antisera from the blood ofthe immunized animal after an appropriate waiting period.
- an animal such as a rabbit, guinea pig, or goat
- an appropriate immunogen and obtaining antisera from the blood ofthe immunized animal after an appropriate waiting period.
- State-of-the-art reviews are provided by Parker, "Radioimmunoassay of Biologically Active Compounds/' Prentice-Hall (Englewood Cliffs, N.J., U.S., 1976); Butler, J. Immunol. Meth. 7: 1-24 (1975); Broughton and Strong, Clin. Chem. 22: 726-732 (1976); and Playfair, et al., Br. Med. Bull. 30: 24-31 (1974).
- Antibodies can also be obtained by somatic cell hybridization techniques, such antibodies being commonly referred to as monoclonal antibodies.
- Monoclonal antibodies may be produced according to the standard techniques of K ⁇ hler and Milstein, Nature 265:495-497, 1975. Reviews of monoclonal antibody techniques are found in Lymphocyte Hybridomas, ed. Melchers, et al. Springer-Verlag (New York 1978), Nature 266: 495 ( 19771 Science 208: 692 (1980), and Methods of Enzvmologv 73 (Part B): 3-46 (1981). Samples of an appropriate immunogen preparation are injected into an animal such as a mouse and, after a sufficient time, the animal is sacrificed and spleen cells obtained.
- the spleen cells of a non-immunized animal can be sensitized to the immunogen in vitro.
- the spleen cell chromosomes encoding the base sequences for the desired immunoglobins can be compressed by fusing the spleen cells, generally in the presence of a non-ionic detergent, for example, polyethylene glycol, with a myeloma cell line.
- a non-ionic detergent for example, polyethylene glycol
- the resulting cells which include fused hybridomas, are allowed to grow in a selective medium, such as HAT-medium, and the surviving immortalized cells are grown in such medium using limiting dilution conditions.
- the cells are grown in a suitable container, e.g., microtiter wells, and the supernatant is screened for monoclonal antibodies having the desired specificity.
- a suitable container e.g., microtiter wells
- Various techniques exist for enhancing yields of monoclonal antibodies such as injection ofthe hybridoma cells into the peritoneal cavity of a mammalian host, which accepts the cells, and harvesting the ascites fluid. Where an insufficient amount ofthe monoclonal antibody collects in the ascites fluid, the antibody is harvested from the blood ofthe host.
- the cell producing the desired antibody can be grown in a hollow fiber cell culture device or a spinner flask device, both of which are well known in the art.
- antibodies can be purified by known techniques such as chromatography, e.g., Protein A chromatography, Protein G chromatography, DEAE chromatography, ABx chromatography, and the like, filtration, and so forth.
- chromatography e.g., Protein A chromatography, Protein G chromatography, DEAE chromatography, ABx chromatography, and the like, filtration, and so forth.
- Antibody to a platelet cell surface glycoprotein receptor an antibody that specifically recognizes an epitope on a platelet cell surface glycoprotein receptor.
- the receptor is GPIb ⁇ and, preferably, the N-terminal portion of GPIb ⁇ .
- the portion ofthe receptor recognized should be at least about 5 nm to about 10 nm from the surface ofthe cell, preferably, at least about 20nm to about 30 nm from the cell surface. However, in some circumstances the portion ofthe receptor recognized by the ligand may be less than about 5 nm from the cell surface.
- the receptor be present at a density of at least about 5000 per cell, usually about 10,000 per cell, more usually, at least about 15,000 per cell, preferably, at least about 20,000 and more preferably, about 25,000 per cell. However, in some circumstances the density ofthe receptor may be less than about 10,000 per cell.
- the antibody when directed against GPIb ⁇ , substantially inhibits von Willebrand factor binding to the receptor, i.e., the antibody inhibits the binding of vWf to the receptor at least about 50 %, and preferably about 90 to about 100 %.
- the antibody preferably is substantially inhibitory of platelet aggregation induced by ristocetin or botrocetin, which means that the antibody preferably inhibits platelet aggregation by at least about 50%, and usually and preferably by about 100 % at saturation. Still more preferably, the antibodies bind glycocalicin. More preferably, the antibody does not substantially interfere with functional aspects ofthe fibrinogen receptor. In other words the antibody does not inhibit platelet agglutination induced by ADP or be inhibited by Ilb/IIIa antagonists, that is reagents that inhibit fibrinogen binding to the Ilb/IIIa receptor. The antibody may also inhibit the binding of thrombin to GPIb ⁇ .
- the present invention may be employed to accurately determine platelet count in a sample. Moreover, there is disagreement as to whether a significant portion of GPIb ⁇ receptors become degraded or internalized in vivo.
- antibodies directed against the GPIb ⁇ receptor permit significant improvement in system controls. In other words, they work well in agglutination reactions that reflect the platelet count. Without meaning to be held to any theory, the effectiveness may be due to the fact that GPIb ⁇ is a high-density receptor and that the immunogenicity ofthe receptor is preserved on fixed, lyophilized platelets.
- antibodies against receptor GPIb ⁇ are preferred in the present invention, antibodies against other receptors may be useful. These receptors include
- antibodies that may be used in the present invention are the following by way of illustration and not limitation: monoclonal antibody from clone 6D1 as disclosed and described by Coller, 1983, supra; monoclonal antibody from clone AN51 as disclosed and described by Ruan, 1981, supra, and available from Dako, Carpenteria CA; monoclonal antibody from clone 4H12 as
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99971092A EP1123510A1 (en) | 1998-10-23 | 1999-10-20 | Method for determining platelet count |
AU12189/00A AU1218900A (en) | 1998-10-23 | 1999-10-20 | Method for determining platelet count |
CA002348612A CA2348612A1 (en) | 1998-10-23 | 1999-10-20 | Method for determining platelet count |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17788498A | 1998-10-23 | 1998-10-23 | |
US09/177,884 | 1998-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000025140A1 true WO2000025140A1 (en) | 2000-05-04 |
Family
ID=22650321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/024670 WO2000025140A1 (en) | 1998-10-23 | 1999-10-20 | Method for determining platelet count |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1123510A1 (en) |
AU (1) | AU1218900A (en) |
CA (1) | CA2348612A1 (en) |
WO (1) | WO2000025140A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000073792A1 (en) * | 1999-05-28 | 2000-12-07 | Sendx Medical, Inc. | Control for methods for determining platelet count and platelet function |
WO2002010771A1 (en) * | 2000-08-01 | 2002-02-07 | Carepoint Diagnostics, Inc. | Analysis of biological samples for platelet activation or coagulation activation markers using microparticules |
US7595169B2 (en) | 2005-04-27 | 2009-09-29 | Accumetrics, Inc. | Method for determining percent platelet aggregation |
US7782447B2 (en) | 2006-07-17 | 2010-08-24 | Hemocue Ab | Enumeration of thrombocytes |
US7790362B2 (en) | 2003-07-08 | 2010-09-07 | Accumetrics, Inc. | Controlled platelet activation to monitor therapy of ADP antagonists |
EP2829878A1 (en) * | 2013-07-23 | 2015-01-28 | Siemens Healthcare Diagnostics Products GmbH | Method for determining GPIb receptor-dependent platelet function |
US9506938B2 (en) | 2003-07-08 | 2016-11-29 | Accumetrics, Inc. | Methods for measuring platelet reactivity of individuals treated with drug eluting stents |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003655A1 (en) * | 1994-07-23 | 1996-02-08 | Boehringer Mannheim Gmbh | Method for the determination of the prethrombotic state |
US5763199A (en) * | 1994-09-29 | 1998-06-09 | Mount Sinai School Of Medicine Of The City University Of New York | Platelet blockade assay |
WO1998041868A1 (en) * | 1997-03-20 | 1998-09-24 | Accumetrics, Inc. | Agglutrimetric assays in blood |
-
1999
- 1999-10-20 EP EP99971092A patent/EP1123510A1/en not_active Withdrawn
- 1999-10-20 AU AU12189/00A patent/AU1218900A/en not_active Abandoned
- 1999-10-20 CA CA002348612A patent/CA2348612A1/en not_active Abandoned
- 1999-10-20 WO PCT/US1999/024670 patent/WO2000025140A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996003655A1 (en) * | 1994-07-23 | 1996-02-08 | Boehringer Mannheim Gmbh | Method for the determination of the prethrombotic state |
US5763199A (en) * | 1994-09-29 | 1998-06-09 | Mount Sinai School Of Medicine Of The City University Of New York | Platelet blockade assay |
WO1998041868A1 (en) * | 1997-03-20 | 1998-09-24 | Accumetrics, Inc. | Agglutrimetric assays in blood |
Non-Patent Citations (2)
Title |
---|
COLLER B S: "INTERACTION OF NORMAL, THROMBASTHENIC, AND BERNARD-SOULIER PLATELETS WITH IMMOBILIYED FIBRINOGEN: DEFECTIVE PLATELET- FIBRINOGEN INTERACTION IN THROMBASTHENIA", BLOOD,US,PHILADELPHIA, PA, vol. 55, no. 2, February 1980 (1980-02-01), pages 169 - 178, XP002911350, ISSN: 0006-4971 * |
MINAMOTO Y. ET AL.: "Detection of platelet adhesion/aggregation to immobilized ligands on microbeads by an aggregometer", THROMBOSIS AND HEMOSTASIS, vol. 76, no. 6, 1996, pages 1072 - 1079, XP002921232 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000073792A1 (en) * | 1999-05-28 | 2000-12-07 | Sendx Medical, Inc. | Control for methods for determining platelet count and platelet function |
WO2002010771A1 (en) * | 2000-08-01 | 2002-02-07 | Carepoint Diagnostics, Inc. | Analysis of biological samples for platelet activation or coagulation activation markers using microparticules |
US7790362B2 (en) | 2003-07-08 | 2010-09-07 | Accumetrics, Inc. | Controlled platelet activation to monitor therapy of ADP antagonists |
US8574828B2 (en) | 2003-07-08 | 2013-11-05 | Accumetrics, Inc. | Controlled platelet activation to monitor therapy of ADP antagonists |
US9341637B2 (en) | 2003-07-08 | 2016-05-17 | Accumetrics Inc. | Controlled platelet activation to monitor therapy of ADP antagonists |
US9506938B2 (en) | 2003-07-08 | 2016-11-29 | Accumetrics, Inc. | Methods for measuring platelet reactivity of individuals treated with drug eluting stents |
US7595169B2 (en) | 2005-04-27 | 2009-09-29 | Accumetrics, Inc. | Method for determining percent platelet aggregation |
US7782447B2 (en) | 2006-07-17 | 2010-08-24 | Hemocue Ab | Enumeration of thrombocytes |
EP2829878A1 (en) * | 2013-07-23 | 2015-01-28 | Siemens Healthcare Diagnostics Products GmbH | Method for determining GPIb receptor-dependent platelet function |
Also Published As
Publication number | Publication date |
---|---|
CA2348612A1 (en) | 2000-05-04 |
AU1218900A (en) | 2000-05-15 |
EP1123510A1 (en) | 2001-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Abrams et al. | Direct detection of activated platelets and platelet-derived microparticles in humans | |
EP2153235B1 (en) | Methods of measuring inhibition of platelet aggregation by thrombin receptor antagonists | |
US9341637B2 (en) | Controlled platelet activation to monitor therapy of ADP antagonists | |
JP2002511925A (en) | Blood agglutination assay | |
JPS61192285A (en) | Monoclonal antibody to activated platelet | |
CN104160273A (en) | Sandwich assay for immunosuppressant drugs | |
Nurden et al. | Markers of platelet activation in coronary heart disease patients | |
US5939276A (en) | Flow cytometry assay for heparin-induced thrombocytopenia | |
CN103026231B (en) | Reagent and reagent kit for measurement of FDP, and measurement method | |
WO2000025140A1 (en) | Method for determining platelet count | |
US20010046685A1 (en) | Control for methods for determining platelet count and platelet function | |
US5486361A (en) | Hybridomas and monoclonal antibodies that speifically bind to GPIB on platelets and inhibit the binding of thrombin to platelets | |
Heilmann et al. | Dog platelets accumulate intracellular fibrinogen as they age | |
Joseph et al. | Platelet activation markers and the primary antiphospholipid syndrome (PAPS) | |
Smink et al. | Immunologic demonstration of a deficiency of Hageman factor-like material in Hageman trait | |
WO2015095426A1 (en) | Detection of endothelial disease | |
EP0437547B1 (en) | Monoclonal antibodies against receptor-induced binding sites on ligands binding to proteins of the cytoadhesin super family | |
Gordz et al. | Effect of desmopressin (DDAVP) on platelet membrane glycoprotein expression in patients with von Willebrand's disease | |
US6168925B1 (en) | GPIIb/IIIa platelet receptors assay | |
WO1996017622A1 (en) | Antibodies which inhibit the binding of thrombin to platelets | |
DK173362B1 (en) | Monoclonal antibody, hybridoma which secretes the antibody, cell culture preparation containing such hybridoma, diagnostics | |
Humbert et al. | Visualization of activation-dependent epitopes on glycoprotein IIb-IIIa complexes of platelets stimulated by thrombin: immunogold staining of ultrathin sections | |
CA2277094A1 (en) | P-selectin assays and methods of use thereof | |
Du et al. | Functional characterization of the ICAM-4-α | |
EP0838034A1 (en) | Immunoassay for determining blood cell activation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 12189 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2348612 Country of ref document: CA Ref country code: CA Ref document number: 2348612 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999971092 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999971092 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999971092 Country of ref document: EP |